So much for the Federal Reserve’s idea that the U.S. economy is prepared for a rate hike… Shortly after the U.S. announced that employers added 155,000 jobs in August 2016 (missing estimates for 181,000) the odds of a September 2016 rate hike dropped to 18% from 82%. Of those jobs, some of the biggest gains…
DetailsHow Are You Preparing For The Great Disruption?
John Maynard Keynes was right. As someone who has read all five parts of The General Theory of Employment, Interest and Money, I can tell you that’s a big claim. Keynes has been portrayed as one of history’s great economic thinkers. His theories are the foundation for the modern financial system that has created so…
DetailsChart of Day: Rigel Pharmaceuticals (RIGL) soars 108%
After a sell-off in the biotech sector, we found a great deal of severely undervalued names trading at extremely low prices. It’s part of the reason why we recommended Rigel Pharmaceuticals (RIGL) at just $1.95 a share in the April 2016 issue of The Cheap Investor. Shares of RIGL are now up 108% after the company…
DetailsEpiPen Price Crisis: Potential Solutions for 3.6 million Americans
“I am running a business. I am a for-profit business. I am not hiding from that.” That was Mylan CEO, Heather Bresch’s recent reaction to the EpiPen cost controversy. And as heartless as that may sound, she’s right. Mylan’s EpiPen essentially has no competition, and that’s why the company has been able to continuously raise…
DetailsMy “Run In” With A Self-Driving Car
When I moved to the Phoenix area, the first thing I noticed is that every road is in squares. Just squares. Endless squares From the city center to 20 or 30 miles in all directions the roads make nothing but squares. Near my place in Scottsdale is an S-curve that’s wildly out of place. When…
DetailsChart of Day: Bovie Medical (BVX) Soars 159%
The summer was one of the most profitable on record for us, too. In fact, since May, here are just some of the wins collected by subscribers: Bovie Medical Corporation (BVX) up 159% Rigel Pharmaceuticals (RIGL) up 29% Goldfield Corporation (GV) up 106% MeetMe Inc. (MEET) up 135% Adverum Biotechnologies (ADVM) up 37% Groupon Inc.…
DetailsEpiPen Debate: Why Drug Delivery System is So Expensive
The pharmaceuticals industry is no stranger to controversy. Plagued with runaway drug prices that have drawn the ire of Americans, the industry has come under fire, most recently from Democratic presidential nominee Hillary Clinton. But it’s not just the high cost of drugs that’s upset her. It’s also the high cost of drug delivery systems.…
DetailsTwo Rules For New Gold Buyers
$106,848 That’s how much it cost to run a full page ad in Section C of the New York Times. A big layout for most businesses. It’s easily justified cost for a wide-release movie. It can also be absorbed in the “branding” efforts of a big companies like Samsung who spend as much as $15…
DetailsThe Dirty (And Profitable) Secret About This Year’s Worst-Performing ETF
Biotech is back…it seems. The NASDAQ Biotechnology Index is up 19% in the last month. However, I’ve got to warn you, a year and a half into the correction, I’m still not buying it at all. Here’s why. The Hidden Biotech Bust In March 2015 your editor warned: The risk/reward of biotech stocks as a…
DetailsChart of Day: The Biotech M&A Boom Continues
In early April 2016, we noted, “Biotech may have had a rough start to the year, lagging many other sectors. But don’t count it out just yet. In fact, buy all you can. The same strong catalysts and fundamentals are still firmly in place. Even though the first quarter of 2016 showed slower M&A activity,…
DetailsHow I’m Preparing For the Next Market Drop
“This is a vote that changes everything.” That’s the quote we took the Financial Times following the Brexit referendum. It has now been two months since the Brexit was approved by voters and, in a way, everything has changed. Running With The Herd We felt a little bit like we were losing our minds watching…
DetailsNote to Federal Reserve: It’s too soon to Raise Rates
The last time the Federal Reserve raised the interest rate was in December 2015. At the time, the central bank was confident the economy was strong enough to handle higher borrowing costs. But as they learned soon after, they were wrong. Their optimism was premature. The economy wasn’t ready. World markets plunged thousands of points,…
Details